Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$296.52
-0.2%
$282.95
$253.30
$346.85
$159.70B0.492.85 million shs2.10 million shs
AstraZeneca PLC stock logo
AZN
AstraZeneca
$70.82
+1.1%
$70.72
$61.24
$87.68
$217.15B0.375.27 million shs3.67 million shs
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$80.15
-0.5%
$79.02
$70.22
$109.00
$78.01B0.7973,281 shs35,518 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$113.24
+2.0%
$107.40
$67.65
$119.96
$138.15B0.297.70 million shs5.23 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+1.38%+2.23%+2.30%+2.03%-4.64%
AstraZeneca PLC stock logo
AZN
AstraZeneca
+0.56%-2.02%-3.92%+4.88%-9.22%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
+0.19%+2.30%+2.01%+3.95%-19.37%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-0.64%-0.60%-1.24%+5.52%+64.41%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
4.5231 of 5 stars
2.22.03.33.94.12.51.3
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.3618 of 5 stars
2.43.01.70.02.90.01.3
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.8854 of 5 stars
0.03.01.70.01.00.01.3
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.7418 of 5 stars
1.43.04.24.14.02.52.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.35
Hold$307.823.81% Upside
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.83
Moderate Buy$85.0020.02% Upside
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
4.00
Strong BuyN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.77
Moderate Buy$111.38-1.64% Downside

Current Analyst Ratings Breakdown

Latest CSLLY, AZN, AMGN, and GILD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$328.00
6/24/2025
Amgen Inc. stock logo
AMGN
Amgen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/24/2025
Amgen Inc. stock logo
AMGN
Amgen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$305.00
5/21/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/20/2025
Amgen Inc. stock logo
AMGN
Amgen
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$288.00
5/16/2025
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$329.00 ➝ $328.00
5/8/2025
Amgen Inc. stock logo
AMGN
Amgen
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/7/2025
Amgen Inc. stock logo
AMGN
Amgen
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$235.00 ➝ $280.00
5/2/2025
Amgen Inc. stock logo
AMGN
Amgen
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$319.00 ➝ $315.00
5/2/2025
Amgen Inc. stock logo
AMGN
Amgen
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
5/2/2025
Amgen Inc. stock logo
AMGN
Amgen
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$324.00 ➝ $320.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.77$30.32 per share9.78$10.93 per share27.13
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B4.06$6.37 per share11.12$13.18 per share5.37
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$14.80B5.24$3.96 per share20.25$20.07 per share3.99
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$28.75B4.90$7.00 per share16.17$15.44 per share7.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$10.9627.0513.862.6917.39%176.11%12.39%8/5/2025 (Estimated)
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.4928.4414.161.2914.14%33.14%12.83%7/29/2025 (Estimated)
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$2.64BN/A0.0019.601.74N/AN/AN/A8/19/2025 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$480M$4.7523.8413.960.7220.76%51.93%17.40%8/6/2025 (Estimated)

Latest CSLLY, AZN, AMGN, and GILD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Amgen Inc. stock logo
AMGN
Amgen
$5.21N/AN/AN/A$8.86 billionN/A
7/29/2025Q2 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.11N/AN/AN/A$14.08 billionN/A
5/1/2025Q1 2025
Amgen Inc. stock logo
AMGN
Amgen
$4.18$4.90+$0.72$3.20$8.05 billion$8.15 billion
4/29/2025Q1 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10$1.24+$0.14$0.93$13.71 billion$13.59 billion
4/24/2025Q1 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.77$1.81+$0.04$1.04$6.77 billion$6.67 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.523.21%N/A86.86%14 Years
AstraZeneca PLC stock logo
AZN
AstraZeneca
$2.062.91%N/A82.73%N/A
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$1.201.50%N/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.162.79%N/A66.53%10 Years

Latest CSLLY, AZN, AMGN, and GILD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.793%6/13/20256/13/20256/27/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
8.70
1.17
0.88
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.65
0.90
0.70
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.45
1.86
0.85
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.16
1.37
1.23

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.03%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.76%
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000537.71 million533.62 millionOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
94,3003.10 billionN/AOptionable
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
32,698968.42 millionN/ANot Optionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,6001.24 billion1.24 billionOptionable

Recent News About These Companies

AHF: Gilead's Greed Costs Latin America HIV Protection

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amgen stock logo

Amgen NASDAQ:AMGN

$296.52 -0.48 (-0.16%)
Closing price 04:00 PM Eastern
Extended Trading
$294.98 -1.54 (-0.52%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$70.82 +0.80 (+1.14%)
Closing price 04:00 PM Eastern
Extended Trading
$70.82 0.00 (0.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

CSL stock logo

CSL OTCMKTS:CSLLY

$80.15 -0.40 (-0.50%)
As of 03:54 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$113.24 +2.18 (+1.96%)
Closing price 04:00 PM Eastern
Extended Trading
$113.38 +0.14 (+0.12%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.